An Open-Label, Multi-Center, Phase IB Study of RO7082859 and Atezolizumab (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Atezolizumab (Primary) ; RO 7082859 (Primary) ; Obinutuzumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 17 Jan 2019 Planned End Date changed from 17 Jun 2023 to 11 May 2021.
- 17 Jan 2019 Planned primary completion date changed from 17 Jun 2023 to 11 May 2021.
- 28 May 2018 New trial record